New Study Reveals Glaucoma Treatment Trends and Health Inequalities in New Zealand
A recent 10-year study has highlighted important trends in how glaucoma is treated across New Zealand. The research shows that a medication called latanoprost is the most common choice for patients, accounting for 40% of all glaucoma prescriptions in the country.
Glaucoma is a serious eye condition that can lead to permanent vision loss if it is not managed correctly. The study analyzed data over a decade to understand how doctors are prescribing treatments and how patients are accessing the care they need to protect their eyesight.
However, the report also identified significant concerns regarding health equity. While treatment rates have increased overall, the data shows that Māori and Pasifika patients continue to face disparities in accessing these essential eye health services compared to other groups.
Health experts suggest that these findings are a call to action for the medical community. Addressing these gaps is vital to ensure that all New Zealanders, regardless of their background, receive the same quality of care and have the best chance to prevent vision loss.
Moving forward, the study encourages policymakers and healthcare providers to focus on improving access to eye care for underserved communities. By identifying these specific barriers, the health system can work toward a more equal future for all New Zealand patients.